BioSpace News Archive

3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, announced completion of the first series of US surgeries in the BalancedBack Total Joint Replacement Investigational Device Exemption pivotal clinical trial.

A New Research on the Artificial Intelligence (AI) in Drug Discovery Market was conducted across a variety of industries in various regions to produce more than 350+ page reports.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced an executive leadership transition.

Adagene Inc. announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy.

Hyperfine, Inc. announced that Dave Scott will step down from his role as President, Chief Executive Officer, and Board Member for personal reasons, effective July 29, 2022.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced a peer-reviewed publication highlighting the potential of its proprietary Cas-CLOVER Site-specific Gene Editing System as a high-efficiency platform for the production of allogeneic CAR-T cells.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its second quarter 2022 results before the market opens on Tuesday, August 2, 2022.

NuVasive, Inc. announced the grand opening of its Singapore Experience Center for the Asia-Pacific region, supporting the Company’s growth strategy to globalize its business.

Wilmington, Delaware, United States: Enzymes are biocatalysts and highly specialized for accelerating various types of chemical reactions without undergoing self-changes.